VVUS - VIVUS, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.4525
-0.0765 (-14.46%)
As of 1:41PM EDT. Market open.
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Gap Down

Gap Down

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close0.5290
Open0.5150
Bid0.4440 x 1000
Ask0.4452 x 1200
Day's Range0.4400 - 0.5200
52 Week Range0.4400 - 4.7500
Volume1,677,336
Avg. Volume908,882
Market Cap8.085M
Beta (5Y Monthly)-0.85
PE Ratio (TTM)N/A
EPS (TTM)-2.7030
Earnings DateAug 04, 2020 - Aug 10, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing. The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020.

  • VVUS: Enterprise Valuation Update
    Zacks Small Cap Research

    VVUS: Enterprise Valuation Update

    By John Vandermosten, CFA NASDAQ:VVUS READ THE FULL VVUS RESEARCH REPORT Debt Restructuring In May 2013, Vivus, Inc. (NASDAQ:VVUS) closed offerings of $250 million of 4.5% convertible debt that became due in May 2020. The conversion rate of the notes is 6.73038 per $1,000 of face value leaving them well out of the money and unable to convert. Without conversion, the notes remained as debt and

  • GlobeNewswire

    VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes. Under the terms of the agreement, the Company will continue to work with IEH Biopharma on an exclusive basis in respect of any restructuring, financing or other material transaction concerning the Company or its assets, with the exception that the Company is granted a 30-day period to refinance and pay in full in cash all amounts due and owing under the Convertible Senior Notes to IEH Biopharma.

  • Thomson Reuters StreetEvents

    Edited Transcript of VVUS earnings conference call or presentation 6-May-20 8:30pm GMT

    Q1 2020 Vivus Inc Earnings Call

  • Zacks Small Cap Research

    VVUS: First Quarter 2020 Results

    By John Vandermosten, CFA NASDAQ:VVUS Vivus, Inc. (NASDAQ:VVUS) released first quarter 2020 results on May 6, 2020 and provided an update of financial and operational results for the period. During the first quarter of the year, total revenues were up 22% to $19.6 million on a year over year basis and up 14% sequentially. First quarter earnings were ($0.49) per share and adjusted earnings ($0.15)

  • GlobeNewswire

    VIVUS Reports First Quarter 2020 Financial Results

    Company to host conference call today at 4:30pm ET CAMPBELL, Calif., May 06, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today reported.

  • GlobeNewswire

    VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020

    CAMPBELL, Calif., May 01, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the first quarter of 2020.

  • GlobeNewswire

    VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of  approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of the agreement, the Company will pay IEH Biopharma $3.8 million in accrued and unpaid interest on the Convertible Senior Notes and IEH Biopharma will grant the Company a 30-day grace period (if not terminated sooner pursuant to the terms of the agreement), beginning today, for payment of the principal amount of the Convertible Senior Notes during which the two parties will work exclusively to attempt to restructure the outstanding principal amount of the Convertible Senior Notes.

  • GlobeNewswire

    VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, research and development and satisfaction of corporate debts. The shares of common stock were offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-227353) previously filed with the Securities and Exchange Commission (the "SEC") on September 14, 2018 and declared effective by the SEC on September 27, 2018.

  • VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules
    PR Newswire

    VitalTech Partners with VIVUS Pharmaceuticals to Accelerate Launch of Telehealth and Remote Patient Monitoring Modules

    VitalTech, a rapidly growing market leader in Virtual Care, announced today its partnership with VIVUS, Inc, a publicly held biopharmaceutical company (Nasdaq: VVUS). Leveraging VitalTech's industry-leading virtual care platform and comprehensive medical device product line, VIVUS plans to rapidly accelerate the launch of its telemedicine, virtual care and remote patient monitoring capabilities.

  • GlobeNewswire

    VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The Company intends to use the net proceeds from this offering for working capital, general corporate purposes, research and development and satisfaction of corporate debts. The shares of common stock are being offered by the Company pursuant to a "shelf" registration statement on Form S-3 (File No. 333-227353) previously filed with the Securities and Exchange Commission (the "SEC") on September 14, 2018 and declared effective by the SEC on September 27, 2018.

  • GlobeNewswire

    VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the accelerated launch of the telemedicine and remote monitoring modules of the VIVUS Health Platform. Participating physicians will be able to use the VIVUS Health Platform to conduct virtual office visits, regardless of whether or not the patient is prescribed a VIVUS product.

  • Thomson Reuters StreetEvents

    Edited Transcript of VVUS earnings conference call or presentation 3-Mar-20 9:30pm GMT

    Q4 2019 Vivus Inc Earnings Call

  • GlobeNewswire

    VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

    - Company to host conference call today at 4:30pm ET - CAMPBELL, Calif., March 03, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today.

  • GlobeNewswire

    VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents

    VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of patient enrollment in a Phase 4 clinical study designed to evaluate the safety and efficacy of Qsymia® (phentermine and topiramate extended-release) capsules CIV in adolescents between the ages of 12 and 17 years who are obese (NCT# 03922945). “Completing enrollment in this study is an important milestone in our ongoing efforts to expand the clinical use of Qsymia based on robust safety and efficacy data,” said Santosh T. Varghese, MD, Senior Vice President, Chief Medical Officer at VIVUS.

  • GlobeNewswire

    VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, announced today that its Korean marketing partner, Alvogen, has launched Qsymia (phentermine and topiramate extended-release) in the Republic of Korea. “We believe that Qsymia has significant unrealized clinical and commercial value, and the South Korean launch of this important tool for helping patients achieve and maintain a healthy body-mass index will advance our strategy for unlocking this potential,” said John Amos, CEO of VIVUS.

  • GlobeNewswire

    VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020

    CAMPBELL, Calif., Feb. 18, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) today announced that it will report financial results and provide a business update for the fourth quarter of 2019.

  • GlobeNewswire

    VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

    VIVUS worked closely with Nordmark Arzneimittel GmbH & Co. KG, its manufacturing partner for PANCREAZE, on the FDA approval pursuant to the terms of the  amended contract manufacturing agreement announced in June 2019. PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions. “The approval of this sNDA is an important milestone for VIVUS and for the patients with EPI we seek to treat,” said John Amos, Chief Executive Officer at VIVUS.

  • VVUS: ZenPep Deal Demonstrates PERT Interest
    Zacks Small Cap Research

    VVUS: ZenPep Deal Demonstrates PERT Interest

    By John Vandermosten, CFA NASDAQ:VVUS On January 27th, Nestlé announced its planned purchase of pancrelipase brands ZenPep and Viokace from Allergan for an undisclosed sum. The drugs are designated pancreatic enzyme replacement therapy (PERT) for patients with insufficient digestive enzymes to breakdown fats and other nutrients. The primary conditions that benefit from PERT include cystic

  • GlobeNewswire

    New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool

    VIVUS, Inc. (VVUS), a biopharmaceutical company, today announced the publication of a new study from the Toolbox Trial (NCT01922934), a real-world clinical trial conducted in urban safety-net primary care clinics offering patients a “toolbox” of cost-effective weight management tools. The study, published in the Journal of General Internal Medicine1 (JGIM), found that a higher proportion of subjects who initially selected Qsymia from the toolbox or added it to their weight management plans during the study period achieved at least a 5% weight loss compared with subjects who never used Qsymia.

  • GlobeNewswire

    VIVUS to Present at Biotech Showcase on January 13, 2020

    CAMPBELL, Calif., Jan. 02, 2020 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer, will.

  • GlobeNewswire

    VIVUS Adopts Stockholder Rights Plan

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in accordance with its terms on November 9, 2019. Under the new rights plan, the terms of which are substantially similar to the terms of the Company’s prior rights plan, VIVUS will issue a dividend of one right for each share of its common stock held by stockholders of record as of the close of business on January 13, 2020.

  • Before You Buy VIVUS, Inc. (NASDAQ:VVUS), Consider Its Volatility
    Simply Wall St.

    Before You Buy VIVUS, Inc. (NASDAQ:VVUS), Consider Its Volatility

    If you're interested in VIVUS, Inc. (NASDAQ:VVUS), then you might want to consider its beta (a measure of share price...

  • GlobeNewswire

    VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity

    VIVUS, Inc. (VVUS) (the “Company”), a biopharmaceutical company, today announced the results of a pharmacokinetic (PK) and pharmacodynamic (PD) study (NCT02714062) demonstrating that Qsymia® (phentermine and topiramate extended-release) capsules CIV has favorable pharmacokinetic, efficacy, and safety/tolerability profiles when used for eight weeks to treat adolescents with obesity. The study was conducted in order to establish dosing levels for the ongoing Phase 4 post-marketing study of Qsymia in obese adolescents.

  • GlobeNewswire

    VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019

    CAMPBELL, Calif., Nov. 25, 2019 -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that John Amos, Chief Executive Officer at VIVUS,.